These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15804925)

  • 41. The 12 Years Preceding Mild Cognitive Impairment Due to Alzheimer's Disease: The Temporal Emergence of Cognitive Decline.
    Mistridis P; Krumm S; Monsch AU; Berres M; Taylor KI
    J Alzheimers Dis; 2015; 48(4):1095-107. PubMed ID: 26402083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The apolipoprotein E genotype predicts longitudinal transitions to mild cognitive impairment but not to Alzheimer's dementia: findings from a nationally representative study.
    Brainerd CJ; Reyna VF; Petersen RC; Smith GE; Kenney AE; Gross CJ; Taub ES; Plassman BL; Fisher GG
    Neuropsychology; 2013 Jan; 27(1):86-94. PubMed ID: 23356599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.
    Petersen RC; Smith GE; Ivnik RJ; Tangalos EG; Schaid DJ; Thibodeau SN; Kokmen E; Waring SC; Kurland LT
    JAMA; 1995 Apr; 273(16):1274-8. PubMed ID: 7646655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.
    Risacher SL; Saykin AJ; West JD; Shen L; Firpi HA; McDonald BC;
    Curr Alzheimer Res; 2009 Aug; 6(4):347-61. PubMed ID: 19689234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cognitive screening and neuropsychological assessment in early Alzheimer's disease.
    Salmon DP; Lange KL
    Clin Geriatr Med; 2001 May; 17(2):229-54. PubMed ID: 11375134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Free and cued selective reminding test predicts progression to Alzheimer's disease in people with mild cognitive impairment.
    Grande G; Vanacore N; Vetrano DL; Cova I; Rizzuto D; Mayer F; Maggiore L; Ghiretti R; Cucumo V; Mariani C; Cappa SF; Pomati S
    Neurol Sci; 2018 Nov; 39(11):1867-1875. PubMed ID: 30051200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease.
    Ringman JM; Medina LD; Rodriguez-Agudelo Y; Chavez M; Lu P; Cummings JL
    Curr Alzheimer Res; 2009 Aug; 6(4):341-6. PubMed ID: 19689233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways.
    Maruyama M; Matsui T; Tanji H; Nemoto M; Tomita N; Ootsuki M; Arai H; Sasaki H
    Arch Neurol; 2004 May; 61(5):716-20. PubMed ID: 15148149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Neuropsychological impairment in the early Alzheimer's disease].
    Traykov L; Rigaud AS; Cesaro P; Boller F
    Encephale; 2007; 33(3 Pt 1):310-6. PubMed ID: 17675928
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease.
    Egerházi A; Berecz R; Bartók E; Degrell I
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):746-51. PubMed ID: 17289240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.
    Amieva H; Le Goff M; Millet X; Orgogozo JM; Pérès K; Barberger-Gateau P; Jacqmin-Gadda H; Dartigues JF
    Ann Neurol; 2008 Nov; 64(5):492-8. PubMed ID: 19067364
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study.
    Amieva H; Letenneur L; Dartigues JF; Rouch-Leroyer I; Sourgen C; D'Alchée-Birée F; Dib M; Barberger-Gateau P; Orgogozo JM; Fabrigoule C
    Dement Geriatr Cogn Disord; 2004; 18(1):87-93. PubMed ID: 15087583
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.
    Aggarwal NT; Wilson RS; Beck TL; Bienias JL; Berry-Kravis E; Bennett DA
    Neurocase; 2005 Feb; 11(1):3-7. PubMed ID: 15804918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.
    Pike KE; Savage G; Villemagne VL; Ng S; Moss SA; Maruff P; Mathis CA; Klunk WE; Masters CL; Rowe CC
    Brain; 2007 Nov; 130(Pt 11):2837-44. PubMed ID: 17928318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EEG Theta Power Is an Early Marker of Cognitive Decline in Dementia due to Alzheimer's Disease.
    Musaeus CS; Engedal K; Høgh P; Jelic V; Mørup M; Naik M; Oeksengaard AR; Snaedal J; Wahlund LO; Waldemar G; Andersen BB
    J Alzheimers Dis; 2018; 64(4):1359-1371. PubMed ID: 29991135
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.
    Drago V; Babiloni C; Bartrés-Faz D; Caroli A; Bosch B; Hensch T; Didic M; Klafki HW; Pievani M; Jovicich J; Venturi L; Spitzer P; Vecchio F; Schoenknecht P; Wiltfang J; Redolfi A; Forloni G; Blin O; Irving E; Davis C; Hårdemark HG; Frisoni GB
    J Alzheimers Dis; 2011; 26 Suppl 3():159-99. PubMed ID: 21971460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuropsychological assessment in the diagnosis of Alzheimer's disease.
    Baldwin S; Farias ST
    Curr Protoc Neurosci; 2009 Oct; Chapter 10():Unit10.3. PubMed ID: 19802814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.